IDG Capital — 2021 Investments
2 investments dated 2021 · listed companies and verified rows first · show all
EdiGene is a biotechnology company developing genome-editing-based therapies, including allogeneic cell therapies and in vivo RNA base editing platforms, alongside a high-throughput genome editing screening platform.
BiotechDeep TechHealthtech
Co-investorsLAVLilly Asia VenturesWI Harper Group3H Health InvestmentAlwin CapitalBioTrack Capital+2 more
Neukio is a biopharmaceutical company developing iPSC-derived cell technology platforms and next-generation off-the-shelf, mass-producible immune cell products (such as NK cells) to treat solid tumors and autoimmune diseases.
BiotechDeep TechHealthtech
Liqun Wang(Founder)
Co-investorsPan-Lin CapitalAlwin CapitalLilly Asia VenturesSherpa Healthcare Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.